A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive). Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

NCT Number	NCT07107178
Lead Sponsor	Biotroy Therapeutics Collaborators: Peking University Cancer Hospital and Institute
Conditions	Advanced Melanoma, Advanced Solid Tumor
Enrollment	58 participants
Start Date	2025-08-08
Primary Completion	2027-05 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2025-08-06